Loading clinical trials...
Loading clinical trials...
The purpose of this study is to assess the safety and tolerability of initiating LCZ696 in heart failure patients with reduced ejection fraction (HF-rEF) using conservative (reaching target dose over ...
Bring this clarity to your next appointment.
Keep all your medical notes and next steps in one place.
Lead Sponsor
Novartis Pharmaceuticals
NCT06148935 · Chronic Heart Failure With Reduced Ejection Fraction
NCT07057466 · Valvular Heart Disease Stenosis and Regurgitation (Diagnosis), Pulmonary Hypertension (Diagnosis), and more
NCT06229678 · Type2diabetes, Heart Failure With Reduced Ejection Fraction
NCT06859970 · Heart Failure, Heart Failure NYHA Class III, and more
NCT06479876 · Heart Failure With Preserved Ejection Fraction, Heart Failure With Reduced Ejection Fraction, and more
Novartis Investigative Site
Anchorage, Alaska
Novartis Investigative Site
Gilbert, Arizona
Novartis Investigative Site
Tucson, Arizona
Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions